Recent Investment Analysts’ Ratings Updates for Alumis (ALMS)

Several analysts have recently updated their ratings and price targets for Alumis (NASDAQ: ALMS):

• 1/7/2026 – Alumis had its price target raised by analysts at Morgan Stanley from $22.00 to $33.00. They now have an “overweight” rating on the stock.
• 1/7/2026 – Alumis had its price target raised by analysts at Guggenheim from $18.00 to $32.00. They now have a “buy” rating on the stock.
• 1/6/2026 – Alumis had its “outperform” rating reaffirmed by analysts at Citigroup Inc..
• 1/6/2026 – Alumis had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $50.00 price target on the stock.
• 1/6/2026 – Alumis had its price target raised by analysts at Leerink Partners from $20.00 to $32.00. They now have an “outperform” rating on the stock.
• 1/6/2026 – Alumis had its “outperform” rating reaffirmed by analysts at UBS Group AG.
• 1/6/2026 – Alumis had its price target raised by analysts at Wells Fargo & Company from $17.00 to $39.00. They now have an “overweight” rating on the stock.
• 12/29/2025 – Alumis had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Alumis had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/18/2025 – Alumis had its price target raised by analysts at HC Wainwright from $14.00 to $20.00. They now have a “buy” rating on the stock.
• 12/15/2025 – Alumis had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Alumis had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/6/2025 – Alumis was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 11/25/2025 – Alumis had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/15/2025 – Alumis was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/13/2025 – Alumis had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Insider Buying and Selling at Alumis

In related news, Director Srinivas Akkaraju purchased 186,377 shares of the firm’s stock in a transaction dated Friday, December 5th. The shares were purchased at an average price of $9.84 per share, with a total value of $1,833,949.68. Following the acquisition, the director directly owned 1,265,253 shares of the company’s stock, valued at approximately $12,450,089.52. This represents a 17.28% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James B. Tananbaum acquired 190,500 shares of the stock in a transaction dated Wednesday, November 19th. The shares were bought at an average price of $6.56 per share, for a total transaction of $1,249,680.00. Following the transaction, the director owned 2,542,003 shares in the company, valued at approximately $16,675,539.68. This represents a 8.10% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 2,788,875 shares of company stock worth $18,352,357 over the last three months. 40.70% of the stock is owned by insiders.

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.